xq
lee
wl
kauffman
k
hanag
wp
matu
ghaeli
n
endo
n
duvallet
c
moniz
k
erickson
tb
chai
pr
thompson
j
alm
ej
abstract
wastewat
surveil
may
repres
complementari
approach
measur
presenc
even
preval
infecti
diseas
capac
clinic
test
limit
moreov
aggreg
populationwid
data
help
inform
model
effort
test
wastewat
collect
major
urban
treatment
facil
massachusett
found
presenc
high
titer
period
march
use
rtqpcr
confirm
ident
pcr
product
direct
dna
sequenc
viral
titer
observ
significantli
higher
expect
base
clinic
confirm
case
massachusett
march
reason
discrep
yet
clear
experi
complet
data
necessarili
indic
clinic
estim
incorrect
approach
scalabl
may
use
model
pandem
futur
outbreak
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
introduct
improv
understand
presenc
preval
popul
level
help
govern
hospit
offici
implement
appropri
polici
mitig
exponenti
spread
diminish
futur
strain
healthcar
facil
despit
pandem
spread
worldwid
broad
access
test
unit
state
us
thu
far
sever
limit
impract
test
everi
us
resid
viru
found
stool
confirm
patient
make
promis
candid
wastewaterbas
epidemiolog
wbe
wbe
help
detect
presenc
pathogen
across
municip
estim
popul
preval
without
individu
test
inform
public
health
offici
efficaci
intervent
close
relat
viru
sarscov
detect
wastewat
chines
hospit
sar
pandem
wbe
use
earli
detect
direct
mitig
diseas
outbreak
israel
egypt
sweden
previous
use
techniqu
measur
map
use
pharmaceut
across
residenti
commun
describ
analyt
techniqu
extract
detect
genet
materi
use
wastewat
collect
treatment
facil
result
collect
sewag
sampl
major
urban
wastewat
treatment
facil
massachusett
sampl
transport
laboratori
conduct
viral
inactiv
enrich
nucleic
acid
extract
rtqpcr
neg
control
use
biobank
wastewat
sampl
treatment
facil
taken
first
us
case
document
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
initi
test
pcr
use
primer
specif
gene
indic
sampl
collect
treatment
facil
march
posit
signal
confirm
signal
identifi
pcr
product
bp
notempl
control
pcr
assay
neg
sanger
sequenc
pcr
product
confirm
ident
match
gene
figur
next
sought
quantifi
viral
titer
sewag
establish
viral
enrich
protocol
use
rtqpcr
use
us
cdc
primerprob
set
target
loci
nucleocapsid
gene
amplifi
cdna
revers
transcrib
viral
rna
tabl
test
differ
step
viral
enrich
process
first
examin
raw
unfilt
sewag
precipit
polyethylen
glycol
peg
recov
bacteri
viral
nucleic
acid
next
look
sampl
taken
um
filter
sewag
consid
materi
collect
filter
filtrat
found
strongest
consist
result
pegprecipit
viral
pellet
um
filtrat
resuspend
trizol
rna
extract
tabl
result
suggest
fairli
simpl
viral
enrich
protocol
suffici
achiev
viral
identif
importantli
includ
pasteur
min
first
step
perform
sampl
contain
open
increas
safeti
protocol
prior
work
indic
min
heat
inactiv
suffici
inactiv
viru
log
unit
shown
possibl
detect
presenc
wastewat
treatment
facil
sampl
next
look
whether
viral
titer
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
sewag
could
quantifi
standard
curv
three
primer
set
show
linear
behavior
log
unit
r
rang
use
dna
standard
nucleocapsid
gene
sought
valid
result
sampl
includ
biobank
sampl
collect
first
known
us
case
januari
could
serv
relev
neg
control
figur
show
estim
viral
titer
per
ml
sewag
treatment
facil
seven
differ
sampl
date
sampl
two
catchment
area
southern
northern
date
four
sampl
first
known
us
case
neg
viru
contrast
sampl
taken
rang
march
march
test
posit
seven
ten
sampl
hit
three
primer
averag
ct
sampl
viru
qpcr
use
dna
probe
provid
cdc
posit
sampl
confirm
presenc
bp
band
pcr
use
gene
primer
data
shown
thu
approach
sensit
enough
detect
viral
titer
similar
current
seen
treatment
facil
catchment
spikein
experi
purifi
viru
need
establish
rigor
limit
detect
current
underway
final
look
quickli
viral
signal
degrad
storag
sampl
receiv
march
sampl
store
reprocess
april
sampl
pasteur
upon
initi
receipt
figur
show
variat
measur
sampl
process
date
variat
sampl
run
clear
trend
toward
lower
signal
later
timepoint
suggest
sampl
store
week
without
signific
degrad
signal
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
discuss
data
suggest
order
magnitud
estim
approxim
viral
particl
per
ml
sewag
conclus
drawn
diseas
preval
first
note
rigor
conclus
depend
number
factor
unknown
thu
addit
experi
requir
calibr
number
nonetheless
estim
abund
base
lowest
observ
valu
across
sampl
copiesml
assum
typic
stool
size
dilut
averag
volum
l
popul
individu
produc
one
stool
per
day
assum
loss
viral
rna
sewer
line
excret
virus
fulli
suspend
sewag
expect
viral
titer
fece
time
higher
sampl
raw
sewag
particl
per
ml
estim
viral
load
stool
posit
patient
still
matter
uncertainti
least
one
recent
public
suggest
level
high
viral
genom
per
ml
fecal
materi
number
would
suggest
roughli
fecal
sampl
treatment
facil
catchment
posit
march
period
number
much
higher
confirm
state
massachusett
similar
preval
obtain
use
individu
counti
repres
wastewat
treatment
facil
catchment
statewid
estim
march
anoth
paper
report
maximum
observ
valu
close
viral
particl
per
ml
singl
fecal
sampl
use
number
instead
would
estim
preval
closer
still
much
higher
number
confirm
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
clinic
case
addit
data
viral
shed
stool
cours
diseas
requir
fulli
interpret
find
discrep
confirm
case
observ
viral
titer
could
aris
number
factor
first
estim
base
number
assumpt
current
subject
signific
uncertainti
discuss
therefor
could
incorrect
howev
note
calcul
conserv
assum
loss
viral
titer
due
degrad
sampl
process
rna
extract
second
estim
viral
titer
per
posit
stool
may
low
small
number
individu
shed
high
level
viru
test
may
requir
extens
test
individu
stool
order
arriv
accur
estim
given
import
assess
fraction
infect
present
symptom
note
result
consist
idea
signific
fraction
case
detect
current
test
algorithm
fraction
may
includ
larg
number
patient
without
symptom
discrimin
possibl
addit
catchment
differ
size
test
integr
data
presenc
absenc
viral
particl
across
catchment
vari
size
within
geograph
region
may
possibl
estim
diseas
preval
independ
know
averag
viral
titer
infect
stool
exampl
diseas
preval
approxim
catchment
area
repres
individu
would
posit
although
case
may
cluster
within
household
addit
experi
model
would
need
deriv
precis
number
experi
requir
sampl
upstream
area
sewag
system
use
special
equip
captur
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
method
hour
composit
sampl
raw
sewag
taken
wastewat
treatment
facil
influent
pasteur
min
inactiv
viru
raw
sewag
filter
um
membran
millipor
sigma
remov
bacteri
cell
debri
filter
discard
initi
test
reveal
littl
viral
rna
filter
g
polyethylen
glycol
wv
millipor
sigma
g
nacl
millipor
sigma
ad
ml
filtrat
centrifug
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
x
g
hour
pellet
visibl
viral
pellet
resuspend
trizol
thermofish
rna
extract
follow
revers
transcript
revers
transcriptas
neb
qpcr
taqman
fast
advanc
master
mix
thermofish
cdc
primer
idt
nucleocapsid
n
gene
posit
control
idt
plasmid
contain
complet
nucleocapsid
gene
use
creat
standard
curv
primer
thank
wastewat
treatment
facil
work
us
provid
sampl
note
highlight
primersprob
use
qpcr
f
forward
r
revers
p
probe
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
highlight
grey
forward
revers
primer
highlight
yellow
align
sequenc
highlight
purpl
mismatch
sequenc
either
primer
first
base
gene
promot
ad
pcr
sf
sr
primer
tabl
result
shown
sequenc
templat
form
northern
influent
result
southern
influent
similar
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
copiesml
copiesml
copiesml
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
process
april
copiesml
process
march
copiesml
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
